Physician profile
Tony Hedges
NPI 1073591848
$2,928.94
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $1,081 · 2021: $702 · 2022: $120 · 2023: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.49 | 2020-2023 | |
| Allergan, INC. | $389.25 | 2019-2020 | |
| Novo Nordisk INC | $302.35 | 2019-2021 | |
| Amgen INC. | $242.95 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $207.46 | 2019-2021 | |
| Mylan Specialty L.P. | $178.54 | 2020-2021 | |
| Astellas Pharma US INC | $135.66 | 2019-2021 | |
| Amarin Pharma, INC. | $107.08 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $92.01 | 2019-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.90 | 2019-2021 | |
| Ethicon US, LLC | $86.98 | 2020 | |
| Lilly USA, LLC | $73.85 | 2019-2022 | |
| Adlon Therapeutics L.P. | $70.05 | 2020-2021 | |
| Glaxosmithkline, LLC. | $44.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.92 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $39.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $38.36 | 2019-2020 | |
| Pfizer INC. | $35.21 | 2019-2021 | |
| Antares Pharma, INC. | $21.32 | 2020 | |
| Cranial Technologies, INC | $21.28 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.49 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.62 | 2019 | |
| Eisai INC. | $11.59 | 2020 | |
| Merck Sharp & Dohme LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Hedges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.